You are here: Home » Companies » News
Business Standard

Zydus Cadila gets USFDA's final approval to market antidepressant drug

The drug, used in treating depression, will be manufactured at the group's formulations facility at SEZ Ahmedabad

Press Trust of India  |  New Delhi 

Zydus acquires derma brand Melgain from Issar Pharma

Drug firm has received final approval from the US health regulator to market tablets used for treatment of depression in the American market.

The company has received final approval from the (USFDA) to market the tablets in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg, Cadila Healthcare, the listed entity of the group said in a filing today.


The drug, used in treating depression, will be manufactured at the group's formulations facility at Ahmedabad, it added.

"The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process by the company," it added.

First Published: Sat, October 07 2017. 14:25 IST
RECOMMENDED FOR YOU